Dexcom Discloses Theft of G7 Sensors, Notifies Users of Potentially Compromised Product
DXCM sits 31% above its 52-week low of $54.11 on light trading volume (0.1× avg).
Summary
Dexcom has uncovered the theft of scrapped G7 sensors, which were subsequently sold by third parties, including PharmSource, LLC. The company is notifying potentially impacted users. This news follows a period of positive developments for Dexcom, including strong Q1 earnings, board appointments, and a new share repurchase program. The theft and unauthorized sale of medical devices, even if scrapped, poses significant reputational and potential legal risks for Dexcom, raising concerns about product integrity and supply chain security. The company will likely face scrutiny regarding the extent of the theft, the number of affected users, and any potential regulatory actions or product recalls.
At the time of this announcement, DXCM was trading at $71.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5B. The 52-week trading range was $54.11 to $89.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.